Bictegravir/lenacapavir
Medication
- 1 min read
- 2 chapters
Related on Lably
Through HIV/AIDS
Bictegravir/lenacapavir was approved for medical use in the United States in August 2026.
Medical uses
Bictegravir/lenacapavir is indicated as a complete regimen for the treatment of HIV-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to bictegravir or lenacapavir.
Sign in to keep reading
One more chapter is free with a Lably account.
Society and culture
Legal status
Bictegravir/lenacapavir was approved for medical use in the United States in August 2026.
Names
Bictegravir/lenacapavir is sold under the brand name Bixlenvo.
More in Health
Food and Drug AdministrationFederal agency of the United States Department of Health and Human ServicesCenters for Disease Control and PreventionUnited States government public health agencyNauseaMedical symptom or conditionSeizurePeriod of symptoms due to excessive or synchronous neuronal brain activityVomitingExpulsion of stomach contents via the mouth or noseIntravenous therapyMedication administered into a vein